Clinical Exome Sequencing in Neurogenetic and Neuropsychiatric Disorders

Overview

Journal Ann N Y Acad Sci

Specialty Science

Date 2015 Aug 8

PMID 26250888

Citations 15

Authors

Brent L Fogel

Hane Lee

Samuel P Strom

Joshua L Deignan

Stanley F Nelson

Affiliations

Soon will be listed here.

Abstract

Exome sequencing has recently been elevated to the standard of care for genetic diagnostic testing, particularly for genetically diverse and clinically heterogeneous disorders. This review provides a clinically oriented discussion of the next-generation sequencing technology that makes exome sequencing possible and how such technology is applied to the diagnosis of Mendelian disease, including clinically significant de novo variation, interpretation of variants of uncertain clinical significance, the future potential for genetic assessments of disease risk, and the substantial benefits in diagnostic efficiency. Important caveats are also discussed, including the implications of incidental or secondary findings detected during exome sequencing and the relationship of exome sequencing to other methods of clinical genomic testing, such as chromosomal microarray and genome sequencing. Overall, the widespread adoption and use of exome sequencing in routine clinical practice is expected to improve diagnosis rates and reduce test costs, while leading to improvements in patient outcomes and a renewed emphasis on disease management.

Citing Articles

Can long-read sequencing tackle the barriers, which the next-generation could not? A review.

Szakallas N, Bartak B, Valcz G, Nagy Z, Takacs I, Molnar B Pathol Oncol Res. 2024; 30:1611676.

PMID: 38818014 PMC: 11137202. DOI: 10.3389/pore.2024.1611676.

Presenting Patterns of Genetically Determined Developmental Encephalopathies With Epilepsy and Movement Disorders: A Single Tertiary Center Retrospective Cohort Study.

Mastrangelo M, Galosi S, Cesario S, Renzi A, Campea L, Leuzzi V Front Neurol. 2022; 13:855134.

PMID: 35795805 PMC: 9251420. DOI: 10.3389/fneur.2022.855134.

Study on the Economic Burden of Neurodevelopmental Diseases on Patients With Genetic Diagnosis.

Xie D, Duan R, Li C, Xie Z, Wang A, Xiong L Front Public Health. 2022; 10:887796.

PMID: 35615033 PMC: 9126321. DOI: 10.3389/fpubh.2022.887796.

A diagnostic ceiling for exome sequencing in cerebellar ataxia and related neurological disorders.

Ngo K, Rexach J, Lee H, Petty L, Perlman S, Valera J Hum Mutat. 2019; 41(2):487-501.

PMID: 31692161 PMC: 7182470. DOI: 10.1002/humu.23946.

Insight on multiple morphological abnormalities of sperm flagella in male infertility: what is new?.

Wang W, Tu C, Tan Y Asian J Androl. 2019; 22(3):236-245.

PMID: 31210147 PMC: 7275805. DOI: 10.4103/aja.aja_53_19.

References

Kauppi K, Westlye L, Tesli M, Bettella F, Brandt C, Mattingsdal M . Polygenic risk for schizophrenia associated with working memory-related prefrontal brain activation in patients with schizophrenia and healthy controls. Schizophr Bull. 2014; 41(3):736-43. PMC: 4393689. DOI: 10.1093/schbul/sbu152. View

Campbell I, Yuan B, Robberecht C, Pfundt R, Szafranski P, McEntagart M . Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. Am J Hum Genet. 2014; 95(2):173-82. PMC: 4129404. DOI: 10.1016/j.ajhg.2014.07.003. View

Thusberg J, Olatubosun A, Vihinen M . Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat. 2011; 32(4):358-68. DOI: 10.1002/humu.21445. View

Fogel B, Lee H, Deignan J, Strom S, Kantarci S, Wang X . Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. JAMA Neurol. 2014; 71(10):1237-46. PMC: 4324730. DOI: 10.1001/jamaneurol.2014.1944. View

Iglesias A, Anyane-Yeboa K, Wynn J, Wilson A, Truitt Cho M, Guzman E . The usefulness of whole-exome sequencing in routine clinical practice. Genet Med. 2014; 16(12):922-31. DOI: 10.1038/gim.2014.58. View

Srivastava S, Cohen J, Vernon H, Baranano K, McClellan R, Jamal L . Clinical whole exome sequencing in child neurology practice. Ann Neurol. 2014; 76(4):473-83. DOI: 10.1002/ana.24251. View

Miller D, Adam M, Aradhya S, Biesecker L, Brothman A, Carter N . Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010; 86(5):749-64. PMC: 2869000. DOI: 10.1016/j.ajhg.2010.04.006. View

Strom S, Lee H, Das K, Vilain E, Nelson S, Grody W . Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory. Genet Med. 2014; 16(7):510-5. PMC: 4079763. DOI: 10.1038/gim.2013.183. View

Fogel B . Interpretation of genetic testing: variants of unknown significance. Continuum (Minneap Minn). 2012; 17(2 Neurogenetics):347-52. PMC: 3587691. DOI: 10.1212/01.CON.0000396975.87637.86. View

10.

Xue Y, Ankala A, Wilcox W, Hegde M . Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2014; 17(6):444-51. DOI: 10.1038/gim.2014.122. View

11.

Albert T, Molla M, Muzny D, Nazareth L, Wheeler D, Song X . Direct selection of human genomic loci by microarray hybridization. Nat Methods. 2007; 4(11):903-5. DOI: 10.1038/nmeth1111. View

12.

Fogel B, Vickrey B, Walton-Wetzel J, Lieber E, Browner C . Utilization of genetic testing prior to subspecialist referral for cerebellar ataxia. Genet Test Mol Biomarkers. 2013; 17(8):588-94. PMC: 3732434. DOI: 10.1089/gtmb.2013.0005. View

13.

Fogh I, Ratti A, Gellera C, Lin K, Tiloca C, Moskvina V . A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2013; 23(8):2220-31. PMC: 3959809. DOI: 10.1093/hmg/ddt587. View

14.

Naj A, Jun G, Reitz C, Kunkle B, Perry W, Park Y . Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol. 2014; 71(11):1394-404. PMC: 4314944. DOI: 10.1001/jamaneurol.2014.1491. View

15.

Keller M, Ferrucci L, Singleton A, Tienari P, Laaksovirta H, Restagno G . Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2014; 71(9):1123-34. PMC: 4566960. DOI: 10.1001/jamaneurol.2014.1184. View

16.

Andreassen O, Harbo H, Wang Y, Thompson W, Schork A, Mattingsdal M . Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol Psychiatry. 2014; 20(2):207-14. PMC: 4356743. DOI: 10.1038/mp.2013.195. View

17.

Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet J, Maroteaux P . Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994; 371(6494):252-4. DOI: 10.1038/371252a0. View

18.

Yang Y, Muzny D, Xia F, Niu Z, Person R, Ding Y . Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014; 312(18):1870-9. PMC: 4326249. DOI: 10.1001/jama.2014.14601. View

19.

Gray V, Kukurba K, Kumar S . Performance of computational tools in evaluating the functional impact of laboratory-induced amino acid mutations. Bioinformatics. 2012; 28(16):2093-6. PMC: 3413386. DOI: 10.1093/bioinformatics/bts336. View

20.

Clark M, Chen R, Lam H, Karczewski K, Chen R, Euskirchen G . Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011; 29(10):908-14. PMC: 4127531. DOI: 10.1038/nbt.1975. View